CRISPR Therapeutics
CRSP
CRSP
64 hedge funds and large institutions have $180M invested in CRISPR Therapeutics in 2017 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
16% more capital invested
Capital invested by funds: $155M → $180M (+$24.5M)
0.68% more ownership
Funds ownership: 24.09% → 24.77% (+0.68%)
97% less call options, than puts
Call options by funds: $27K | Put options by funds: $983K
Holders
64
Holding in Top 10
6
Calls
$27K
Puts
$983K
Top Buyers
| 1 | +$10.2M | |
| 2 | +$2.71M | |
| 3 | +$2.38M | |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$1.75M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.61M |
Top Sellers
| 1 | -$12.7M | |
| 2 | -$8.43M | |
| 3 | -$457K | |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$309K |
| 5 |
PCMM
Private Capital Management (Minnesota)
Eagan,
Minnesota
|
-$80K |